BACKGROUND: International consensus diagnostic criteria (ICDC) have been proposed to classify autoimmune pancreatitis (AIP) in type 1, type 2, or not otherwise specified. OBJECTIVE: Aim was to apply the ICDC to an Italian series of patients to evaluate the incidence and clinical profiles among different subtypes of AIP. METHODS: we re-evaluated and classified 92 patients diagnosed by Verona criteria, according to the ICDC. RESULTS: Out of 92 patients, 59 (64%) were diagnosed as type 1, 17 (18%) as type 2, and 15 (16%) as not otherwise specified according to the ICDC. A significant difference between type 1 and type 2 were found for age (54.5 ± 14.5 vs. 34.4 ± 13.9 respectively; p < 0.0001), male sex (76 vs. 47%; p = 0.007), jaundice (66 vs. 18%; p = 0.002) and acute pancreatitis (9 vs. 47%; p < 0.0001), elevated serum IgG4 levels (85 vs. 7%; p < 0.0001), inflammatory bowel disease (8 vs. 82%; < 0.0001), and relapse of the disease (34 vs. 6%; p = 0.058). Imaging and response to steroids in the not-otherwise-specified group were similar to type 1 and 2. CONCLUSIONS: Type 1 has a different clinical profile from type 2 autoimmune pancreatitis. The not-otherwise-specified group has peculiar clinical features which are shared both with type 1 or type 2 groups.
BACKGROUND: International consensus diagnostic criteria (ICDC) have been proposed to classify autoimmune pancreatitis (AIP) in type 1, type 2, or not otherwise specified. OBJECTIVE: Aim was to apply the ICDC to an Italian series of patients to evaluate the incidence and clinical profiles among different subtypes of AIP. METHODS: we re-evaluated and classified 92 patients diagnosed by Verona criteria, according to the ICDC. RESULTS: Out of 92 patients, 59 (64%) were diagnosed as type 1, 17 (18%) as type 2, and 15 (16%) as not otherwise specified according to the ICDC. A significant difference between type 1 and type 2 were found for age (54.5 ± 14.5 vs. 34.4 ± 13.9 respectively; p < 0.0001), male sex (76 vs. 47%; p = 0.007), jaundice (66 vs. 18%; p = 0.002) and acute pancreatitis (9 vs. 47%; p < 0.0001), elevated serum IgG4 levels (85 vs. 7%; p < 0.0001), inflammatory bowel disease (8 vs. 82%; < 0.0001), and relapse of the disease (34 vs. 6%; p = 0.058). Imaging and response to steroids in the not-otherwise-specified group were similar to type 1 and 2. CONCLUSIONS: Type 1 has a different clinical profile from type 2 autoimmune pancreatitis. The not-otherwise-specified group has peculiar clinical features which are shared both with type 1 or type 2 groups.
Authors: H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: Terumi Kamisawa; Suresh T Chari; Samuel A Giday; Myung-Hwan Kim; Jae Bock Chung; Kyu Taek Lee; Jens Werner; Frank Bergmann; Markus M Lerch; Julia Mayerle; Tilman Pickartz; Matthias Lohr; Alexander Schneider; Luca Frulloni; George J M Webster; D Nageshwar Reddy; Wei-Chih Liao; Hsiu-Po Wang; Kazuichi Okazaki; Tooru Shimosegawa; Guenter Kloeppel; Vay Liang W Go Journal: Pancreas Date: 2011-08 Impact factor: 3.327
Authors: Gokulakrishnan Balasubramanian; Aravind Sugumar; Thomas C Smyrk; Naoki Takahashi; Jonathan E Clain; Ferga C Gleeson; Phil A Hart; Michael J Levy; Randall K Pearson; Bret T Petersen; Mark D Topazian; Santhi S Vege; Suresh T Chari Journal: Pancreatology Date: 2012-05-11 Impact factor: 3.996
Authors: Karthik Ravi; Suresh T Chari; Santhi S Vege; William J Sandborn; Thomas C Smyrk; Edward V Loftus Journal: Inflamm Bowel Dis Date: 2009-09 Impact factor: 5.325
Authors: T Kamisawa; T Shimosegawa; K Okazaki; T Nishino; H Watanabe; A Kanno; F Okumura; T Nishikawa; K Kobayashi; T Ichiya; H Takatori; K Yamakita; K Kubota; H Hamano; K Okamura; K Hirano; T Ito; S B H Ko; M Omata Journal: Gut Date: 2009-04-26 Impact factor: 23.059
Authors: Sara Nikolic; Marco Lanzillotta; Nikola Panic; Torkel B Brismar; Carlos Fernández Moro; Gabriele Capurso; Emanuel Della Torre; J-Matthias Löhr; Miroslav Vujasinovic Journal: United European Gastroenterol J Date: 2022-05-08 Impact factor: 6.866